EcoDrugPlus

Janus Kinase 2b

Ensembl ID : ENSAPEG00000013219
Gene Symbol: JAK2B
1 Cross references
194 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSAPEG00000022173
Gene Symbol: KITB
1 Cross references
207 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSAPEG00000005764
Gene Symbol: LYN
1 Cross references
196 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSAPEG00000007249
Gene Symbol: MAPKAPK2
2 Cross references
186 Possible Orthologues:

Mapk Activated Protein Kinase 2b

Ensembl ID : ENSAPEG00000011445
Gene Symbol: MAPKAPK2B
1 Cross references
174 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSAPEG00000020350
Gene Symbol: MAPKAPK5
1 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSAPEG00000007745
Gene Symbol: MKNK2B
1 Cross references
208 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSAPEG00000001835
Gene Symbol: MCL1B
1 Cross references
212 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSAPEG00000018985
Gene Symbol: MDM2
1 Cross references
258 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSAPEG00000013480
Gene Symbol: MET
1 Cross references
204 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog (S. Cerevisiae)

Ensembl ID : ENSAPEG00000002462
Gene Symbol: MLST8
1 Cross references
195 Possible Orthologues:

N-Acetylated Alpha-Linked Acidic Dipeptidase 2

Ensembl ID : ENSAPEG00000017110
Gene Symbol: NAALAD2
1 Cross references
339 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).